Literature DB >> 19164423

Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report.

Michal Kasher-Meron, Yosef Uziel, Howard Amital.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19164423     DOI： 10.1093/rheumatology/ken492

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  10 in total

1.  A successful treatment of juvenile idiopathic arthritis with rituximab: A report of two cases.

Authors:  Khadija Berrada; Fatima Ezzahra Abourazzak; Imane El Mezouar; Faiza Lazrak; Nacira Aradoini; Latifa Tahiri; Taoufik Harzy
Journal:  Eur J Rheumatol       Date:  2014-12-01

2.  Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis.

Authors:  Ekaterina I Alexeeva; Saniya I Valieva; Tatyana M Bzarova; Elena L Semikina; Kseniya B Isaeva; Alexander O Lisitsyn; Rina V Denisova; Evgeniya G Chistyakova
Journal:  Clin Rheumatol       Date:  2011-03-08       Impact factor: 2.980

Review 3.  The safety profile of biologic therapies for juvenile idiopathic arthritis.

Authors:  Philip J Hashkes; Yosef Uziel; Ronald M Laxer
Journal:  Nat Rev Rheumatol       Date:  2010-08-31       Impact factor: 20.543

Review 4.  [The importance of biologicals in the treatment of SoJIA].

Authors:  G Dückers; T Niehues
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

5.  Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors:  Maya H Buch; Josef S Smolen; Neil Betteridge; Ferdinand C Breedveld; Gerd Burmester; Thomas Dörner; Gianfranco Ferraccioli; Jacques-Eric Gottenberg; John Isaacs; Tore K Kvien; Xavier Mariette; Emilio Martin-Mola; Karel Pavelka; Paul P Tak; Desiree van der Heijde; Ronald F van Vollenhoven; Paul Emery
Journal:  Ann Rheum Dis       Date:  2011-03-06       Impact factor: 19.103

Review 6.  Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.

Authors:  William G Ambler; Kabita Nanda; Karen Brandt Onel; Susan Shenoi
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

7.  [B-cell targeted therapy for children and adolescents with rheumatic diseases].

Authors:  H Morbach; H J Girschick
Journal:  Z Rheumatol       Date:  2013-05       Impact factor: 1.372

8.  Systemic arthritis in children: a review of clinical presentation and treatment.

Authors:  R Gurion; T J A Lehman; L N Moorthy
Journal:  Int J Inflam       Date:  2011-12-25

Review 9.  Treatment of juvenile idiopathic arthritis: a revolution in care.

Authors:  Matthew L Stoll; Randy Q Cron
Journal:  Pediatr Rheumatol Online J       Date:  2014-04-23       Impact factor: 3.054

10.  Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.

Authors:  Lianne Kearsley-Fleet; Rebecca Davies; Eileen Baildam; Michael W Beresford; Helen E Foster; Taunton R Southwood; Wendy Thomson; Kimme L Hyrich
Journal:  Rheumatology (Oxford)       Date:  2016-01-04       Impact factor: 7.580
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.